Last reviewed · How we verify
Technetium[99mTc] Methylenediphosphonate Injection
Technetium-99m methylenediphosphonate is a radiopharmaceutical that binds to bone mineral and is used for skeletal scintigraphy to detect areas of altered bone metabolism.
Technetium-99m methylenediphosphonate is a radiopharmaceutical that binds to bone mineral and is used for skeletal scintigraphy to detect areas of altered bone metabolism. Used for Skeletal scintigraphy for detection of bone metastases, Evaluation of bone infections (osteomyelitis), Assessment of fractures and stress injuries.
At a glance
| Generic name | Technetium[99mTc] Methylenediphosphonate Injection |
|---|---|
| Also known as | 99mTc-MDP Injection |
| Sponsor | HTA Co., Ltd. |
| Drug class | Radiopharmaceutical bone imaging agent |
| Target | Bone hydroxyapatite mineral |
| Modality | Small molecule |
| Therapeutic area | Nuclear Medicine / Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
The methylenediphosphonate (MDP) moiety has a high affinity for hydroxyapatite in bone mineral, allowing the technetium-99m radionuclide to accumulate in areas of increased osteogenesis and blood flow. This enables gamma camera imaging to visualize bone lesions, fractures, infections, and metabolic abnormalities. The radioisotope emits gamma radiation that is detected to create diagnostic images of skeletal pathology.
Approved indications
- Skeletal scintigraphy for detection of bone metastases
- Evaluation of bone infections (osteomyelitis)
- Assessment of fractures and stress injuries
- Evaluation of metabolic bone disease
Common side effects
- Radiation exposure
- Allergic reaction to technetium complex
- Injection site reactions